of Plavix((R)), Myslee((R)) and Allegra((R)), despite the sales growth comparison being subdued by the fact that the 2008 second-quarter comparative included sales of the active ingredient of Aprovel((R)) to our local partners. Latin America, where net sales rose by 5.7%, was boosted by the acquisition of Medley. However, our performance in Brazil and Mexico was adversely affected by the economic situation, which led to inventory rundowns of some products in distribution channels. First-half net sales in the Other Countries region were up 9.4%, with Japan and China reporting growth of 10.2% (to euro 952 million) and 35.1% (to euro 259 million) respectively.
Second-quarter net sales in emerging markets(5) were euro 1,855 million, an increase of 20.1% (or 6.3% on a constant structure basis and at constant exchange rates). First-half emerging-market net sales were 14.1% higher at euro 3,470 million.
(5) World excluding North America, Western Europe (France, Germany, United Kingdom, Italy, Spain, Greece, Cyprus, Malta, Belgium, Portugal, Netherlands, Austria, Switzerland, Ireland, Finland, Norway, Iceland, Denmark), Japan, Australia and New Zealand.
Very strong results due to sales growth and tight cost control
2009 second-quarter financial results
Adjusted income statement excluding selected items
Sanofi-aventis generated second-quarter net sales of euro 7,438 million, up 11.2% on a reported basis. "Other revenues" rose by 25.5%, reflecting a good performance by Plavix((R)) in the United States and the appreciation of the U.S. dollar.
Gross profit came to euro 5,964 million, an increase of 13.6%, or of 7.0% at constant exchange rates. The ratio of cost of sales to net sales improved by 1.2 points to 24.6%, mainly due to the effect of exchange rates.
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Related biology technology :1
. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)2
. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP3
. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award4
. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time5
. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster6
. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia7
. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis8
. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment9
. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation10
. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients11
. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26